- Home
- TNGX vs FSLY Comparison
TNGX vs FSLY Comparison
Compare TNGX & FSLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- FSLY
- Stock Information
- Founded
- TNGX 2014
- FSLY 2011
- Country
- TNGX United States
- FSLY United States
- Employees
- TNGX N/A
- FSLY N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- FSLY Computer Software: Prepackaged Software
- Sector
- TNGX Health Care
- FSLY Technology
- Exchange
- TNGX Nasdaq
- FSLY Nasdaq
- Market Cap
- TNGX 351.2M
- FSLY 1.2B
- IPO Year
- TNGX N/A
- FSLY 2019
- Fundamental
- Price
- TNGX $5.87
- FSLY $7.29
- Analyst Decision
- TNGX Strong Buy
- FSLY Hold
- Analyst Count
- TNGX 6
- FSLY 10
- Target Price
- TNGX $12.20
- FSLY $8.31
- AVG Volume (30 Days)
- TNGX 2.9M
- FSLY 3.3M
- Earning Date
- TNGX 08-06-2025
- FSLY 08-06-2025
- Dividend Yield
- TNGX N/A
- FSLY N/A
- EPS Growth
- TNGX N/A
- FSLY N/A
- EPS
- TNGX N/A
- FSLY N/A
- Revenue
- TNGX $40,990,000.00
- FSLY $554,630,000.00
- Revenue This Year
- TNGX N/A
- FSLY $10.52
- Revenue Next Year
- TNGX N/A
- FSLY $6.76
- P/E Ratio
- TNGX N/A
- FSLY N/A
- Revenue Growth
- TNGX 10.09
- FSLY 6.26
- 52 Week Low
- TNGX $1.03
- FSLY $4.65
- 52 Week High
- TNGX $12.02
- FSLY $12.08
- Technical
- Relative Strength Index (RSI)
- TNGX 74.27
- FSLY 54.02
- Support Level
- TNGX $5.34
- FSLY $6.90
- Resistance Level
- TNGX $5.63
- FSLY $7.38
- Average True Range (ATR)
- TNGX 0.50
- FSLY 0.23
- MACD
- TNGX -0.04
- FSLY 0.03
- Stochastic Oscillator
- TNGX 84.15
- FSLY 90.09
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About FSLY Fastly Inc.
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2024.